Vice President Business Development

Job Responsibilities (Vice President Business Development) :

A senior-level Business Development (BD) role in pharma (20+ years’ experience) with focus on driving strategic growth, in-licensing/out-licensing, CDMO/CMO partnerships, and managing domestic portfolios.

Key responsibilities include identifying market trends, negotiating high-value contracts, and leading cross-functional teams to expand market share in regulated/emerging markets.

• Strategic Growth & BD Strategy: Define and execute global/domestic BD strategies to achieve revenue, profitability, and EBITDA targets.
• Partnership Management: Identify, evaluate, and secure new business opportunities, including in-licensing, out-licensing, joint ventures, and strategic alliances.
• CDMO/CMO Leadership: Lead business development activities for CDMO/CMO services, focusing on formulations (OSD, liquids, etc.).
• Contract Negotiation: Negotiate, structure, and execute complex licensing agreements, technology transfers, and master service agreements.
• Market Intelligence: Monitor competitor activities, market dynamics, and regulatory developments (e.g., US, EU, APAC) to anticipate challenges and opportunities.
• Relationship Management: Cultivate relationships with stakeholders in multinational pharma and biotech companies.
• Mentorship: Provide leadership to junior BD team members, fostering a results-driven culture.

Qualifications & Skills

• Education: Master’s degree in Business Administration (MBA), Pharmacy, or Life Sciences or any relevant experience
• Experience: Minimum 20 years in pharmaceutical business development, licensing, or strategic alliances, with a proven track record of deal closures.
• Domain Expertise: Strong understanding of pharmaceutical formulations, regulatory environments, and intellectual property portfolios.
• Skills: Exceptional negotiation, strategic planning, and interpersonal communication skills.

Typical KPIs

• Revenue growth and market penetration.
• Number of new partnerships/licensing deals executed.
• Portfolio expansion in key therapeutic areas.